Liquidia Corporation

NASDAQ:LQDA

Biotechnology

Healthcare
$56.40 +0.34%

+$0.23 today

Market cap
$5.08B
Beta
0.59
P/E (TTM)
271.8
EPS (TTM)
$0.25
52W Low $11.85High $73.22

Volume 1.22M

Average 1.50M

LQDA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Liquidia CorporationNASDAQ: LQDA

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit grows, but more slowly than its trailing trend

Q2 FY2026 gross profit of $160.13M rose 2022.3% year over year, behind the +2967.4% change in trailing-twelve-month gross profit. Sequentially, it rose 32.6% from the prior quarter. Over 3 fiscal years it compounded at +123.0% a year.

Context

  • Gross profit amounted to 91.6% of revenue in FY2025, up 33.6 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2022.3% toward the trailing-twelve-month pace of +2967.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$160.13M+32.6% QoQ
Last fiscal yearDec 2025
$145.08M+1687.3% YoY
LTMJun 2026
$416.98M+2967.4% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2022.3%——
1 year+1687.3%——
3-year CAGR+123.0%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
145.08M USD
Year-over-year change
+1687.3%
4-year CAGR
+96.0%

Gross Profit vs competitors

How LQDA compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +2967.4% is the highest of 4, against a peer median of -0.8%.
  • Gross profit amounts to 92.5% of revenue for LQDA, versus a peer median of 86.1%.
LQDA Competitors
Gross Profit for LQDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
UTHRUnited Therapeutics CorporationLTM Jun 2026$2.72B USD-0.8%+16.1%86.1%
INSMInsmed IncorporatedLTM Jun 2026$947.34M USD+214.3%+36.3%83.3%
LQDALiquidia CorporationLTM Jun 2026$416.98M USD+2967.4%+123.0%92.5%
VCREVicore Pharma Holding ABLTM Jun 2026SEK 1.33M SEK-47.7%—100.0%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding LQDA) —-0.8%+26.2%86.1%

Competitors are the stored peer set for LQDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.85M15.94M17.49M14M158.32M
Cost of Revenue3.02M2.86M2.89M5.88M13.24M
Gross Profit9.83M13.08M14.6M8.12M145.08M
Gross Margin76.5%82.1%83.5%58.0%91.6%
Research & Development20.52M19.44M43.24M47.84M39.28M
Selling, General & Admin23.11M32.41M44.74M81.57M157.18M
Operating Expenses43.63M51.85M87.98M129.41M196.45M
Depreciation & Amortization5.61M3.65M2.18M2.2M1.53M
EBITDA(28.21M)(35.03M)(70.05M)(115.71M)(43.22M)
EBITDA Margin-219.4%-219.8%-400.6%-826.7%-27.3%
Operating Income(33.8M)(38.77M)(73.38M)(121.29M)(51.38M)
Operating Margin-263.0%-243.3%-419.6%-866.6%-32.5%
Interest Income33K1.09M3.47M7.65M6.62M
Interest Expense762K2.34M6.27M12.49M24.17M
Other Income / Expenses(782K)(2.25M)(5.12M)(9.1M)(17.55M)
Income Before Tax(34.58M)(41.02M)(78.5M)(130.39M)(68.92M)
Pre-Tax Margin-269.0%-257.4%-448.9%-931.7%-43.5%
Income Tax Expense00000
Net Income(34.58M)(41.02M)(78.5M)(130.39M)(68.92M)
Net Margin-269.0%-257.4%-448.9%-931.7%-43.5%
EPS (Basic)(0.70)(0.67)(1.21)(1.66)(0.80)
EPS (Diluted)(0.70)(0.67)(1.21)(1.66)(0.80)
Weighted Avg Shares49.68M60.96M64.99M78.71M86.06M
Weighted Avg Shares (Diluted)49.68M60.96M64.99M78.71M86.06M

Liquidia Corporation

NASDAQ:LQDA

Intrinsic Alpha fair value

Locked

Current Price

$56.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.